01:05 , Feb 16, 2017 |  BC Innovations  |  Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
21:02 , Jan 27, 2017 |  BC Week In Review  |  Company News

UCSD, U of Manitoba, St. Boniface Hospital Albrechtsen Research Center, WinSanTor deal

The organizations granted WinSanTor an exclusive license to develop and commercialize small molecule antagonists of muscarinic receptor to treat peripheral neuropathy. The lead compound, WST-057 , is in Phase I trials for the indication, with...